Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?
Yang CHEN1
Lu-Ying GUO1
Ling-Fei ZHAO1
Yan-Hong MA1
Xue-Ling ZHU2
Ying XU1
Jiang-Hua CHEN1
1.Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China;The Third Grade Laboratory under the National State, Administration of Traditional Chinese Medicine, Zhejiang, China;Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China;National Key Clinical Department of Kidney Diseases, Institute of Nephrology, Zhejiang Un2.State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang, China;National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China;Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine,Zhejiang, C
摘要：1 Introduction
Chronic kidney disease(CKD)often coexists with or is a complication of cardiovascular disease.Previous studies have shown that CKD increases the risk of cardiovascular death and all-cause death and was considered to be a risk equivalent of coronary heart disease.[1,2]Adjusted for con-founders,decreased glomerular filtration rate(GFR)and increased albuminuria are both independent risk factors for cardiovascular events.[3,4]The risk for cardiovascular death linearly increases with the decline of GFR in a certain range(＜ 70 mL/min per 1.73 m2)and the increase of albuminuria without a threshold effect.[3]
机标关键词：
论文发表日期：2020-12-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 782-786 )
英文信息